Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia

• Published in: Microbiology and immunology Vol. 61; no. 2; p. 64
• Main Authors: Hamaoka, Saeko, Naito, Yoshifumi, Katoh, Hideya, Shimizu, Masaru, Kinoshita, Mao, Akiyama, Koichi, Kainuma, Atsushi, Moriyama, Kiyoshi, Ishii, Ken J, Sawa, Teiji
• Format: Journal Article
• Language: English
• Published: Australia 01.02.2017
• Subjects: Adjuvants, Immunologic - administration & dosage; Aluminum Hydroxide - administration & dosage; Animals; Antigens, Bacterial - immunology; Bacterial Load; Bacterial Toxins - immunology; Freund's Adjuvant - administration & dosage; Lung - microbiology; Lung - pathology; Male; Mice; Mice, Inbred ICR; Oligodeoxyribonucleotides - administration & dosage; Pneumonia, Bacterial - prevention & control; Pore Forming Cytotoxic Proteins - immunology; Pseudomonas aeruginosa - immunology; Pseudomonas Infections - prevention & control; Pseudomonas Vaccines - administration & dosage; Pseudomonas Vaccines - immunology; Survival Analysis; Treatment Outcome; infection immunity; toxin; vaccines; bacterial components
• ISSN: 1348-0421
• DOI: 10.1111/1348-0421.12467

Vaccination against the type III secretion system of P. aeruginosa is a potential prophylactic strategy for reducing the incidence and improving the poor prognosis of P. aeruginosa pneumonia. In this study, the efficacies of three different adjuvants, Freund's adjuvant (FA), aluminum hydroxide (alum) and CpG oligodeoxynucleotide (ODN), were examined from the viewpoint of inducing PcrV-specific immunity against virulent P. aeruginosa. Mice that had been immunized intraperitoneally with recombinant PcrV formulated with one of the above adjuvants were challenged intratracheally with a lethal dose of P. aeruginosa. The PcrV-FA immunized group attained a survival rate of 91%, whereas the survival rates of the PcrV-alum and PcrV-CpG groups were 73% and 64%, respectively. In terms of hypothermia recovery after bacterial instillation, PcrV-alum was the most protective, followed by PcrV-FA and PcrV-CpG. The lung edema index was lower in the PcrV-CpG vaccination group than in the other groups. PcrV-alum immunization was associated with the greatest decrease in myeloperoxidase in infected lungs, and also decreased the number of lung bacteria to a similar number as in the PcrV-FA group. There was less neutrophil recruitment in the lungs of mice vaccinated with PcrV-alum or PcrV-CpG than in those of mice vaccinated with PcrV-FA or PcrV alone. Overall, in terms of mouse survival the PcrV-CpG vaccine, which could be a relatively safe next-generation vaccine, showed a comparable effect to the PcrV-alum vaccine.